<SEC-DOCUMENT>0001206774-16-005864.txt : 20160505
<SEC-HEADER>0001206774-16-005864.hdr.sgml : 20160505
<ACCEPTANCE-DATETIME>20160505161520
ACCESSION NUMBER:		0001206774-16-005864
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160505
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160505
DATE AS OF CHANGE:		20160505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		161623860

	BUSINESS ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>geron_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<BR>
<P align=center><B><FONT face="Times New Roman" size=2>UNITED
STATES<BR></FONT></B><B><FONT face="Times New Roman" size=2>SECURITIES AND
EXCHANGE COMMISSION<BR>WASHINGTON, D.C. 20549 <BR>___________<BR></FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>FORM 8-K </FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>CURRENT
REPORT<BR></FONT></B><B><FONT face="Times New Roman" size=2>PURSUANT TO SECTION
13 OR 15(d) OF THE<BR>SECURITIES EXCHANGE ACT OF 1934</FONT></B><FONT face="Times New Roman" size=2> </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>Date of Report (Date of
earliest event reported): </FONT><B><FONT face="Times New Roman" size=2>May 5,
2016</FONT></B><FONT face="Times New Roman" size=2> </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>GERON
CORPORATION<BR></FONT></B><FONT face="Times New Roman" size=2>(Exact name of
registrant as specified in its charter) </FONT></P>
<TABLE style="LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><B><FONT face="Times New Roman" size=2>Delaware</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><B><FONT face="Times New Roman" size=2>0-20859</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><B><FONT face="Times New Roman" size=2>75-2287752</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>(State or other jurisdiction</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>(Commission File Number)</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>(IRS Employer</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>of incorporation)</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="33%"><FONT face="Times New Roman" size=2>Identification
No.)</FONT></TD></TR></TABLE><BR>
<P align=center><B><FONT face="Times New Roman" size=2>149 COMMONWEALTH DRIVE,
SUITE 2070<BR>MENLO PARK, CALIFORNIA 94025<BR></FONT></B><FONT face="Times New Roman" size=2>(Address of principal executive offices, including
zip code) </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>(650)
473-7700<BR></FONT></B><FONT face="Times New Roman" size=2>(Registrant&#146;s
telephone number, including area code) </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>N/A<BR></FONT></B><FONT face="Times New Roman" size=2>(Former name or former address, if changed since
last report) </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions: </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>&#9744;</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>Written communications pursuant to Rule 425 under the Securities
      Act (17 CFR 230.425)</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%"></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>&#9744;</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%"></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>&#9744;</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%"></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>&#9744;</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="98%"><FONT face="Times New Roman" size=2>Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><B><FONT face="Times New Roman" size=2>Item 2.02 Results of
Operations and Financial Condition </FONT></B></P>
<P style="TEXT-INDENT: 15pt" align=left><FONT face="Times New Roman" size=2>Geron Corporation (the &#147;Company&#148;) is furnishing this information under
Item 2.02 of Form 8-K. </FONT></P>
<P style="TEXT-INDENT: 15pt" align=left><FONT face="Times New Roman" size=2>The
information in this Current Report, including Exhibit 99.1, is being furnished
and shall not be deemed &#147;filed&#148; for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to
the liabilities of that section. The information in this Current Report,
including Exhibit 99.1, shall not be incorporated by reference into any
registration statement or other document filed pursuant to the Securities Act of
1933, as amended, or the Exchange Act. </FONT></P>
<P style="TEXT-INDENT: 15pt" align=left><FONT face="Times New Roman" size=2>On May 5, 2016, the Company issued a press release announcing its financial results for the three
months ended March 31, 2016. A copy of the press release is attached as Exhibit 99.1.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Item 9.01 Financial
Statements and Exhibits</FONT></B></P>
<P style="TEXT-INDENT: 15pt" align=left><FONT face="Times New Roman" size=2>(d)
Exhibits</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=2>Exhibit
No.</FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%"><B><FONT face="Times New Roman" size=2>Description</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>99.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="96%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Press release dated May 5,
  2016.</FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>SIGNATURE </FONT></B></P>
<P style="TEXT-INDENT: 15pt" align=left><FONT face="Times New Roman" size=2>Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized. </FONT></P>
<TABLE style="LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face="Times New Roman" size=2>GERON
      CORPORATION</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=4>&nbsp;</TD></TR>
  <TR>
    <TD width="100%" colSpan=4>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>Date: May 5,
      2016</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>By:</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="25%">
      <P align=left><FONT face="Times New Roman" size=2>/s/ Stephen N.
      Rosenfield</FONT></P></TD>
    <TD noWrap align=left width="24%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%">&nbsp;</TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>Name:&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=left width="49%" colSpan=2>
      <P align=left><FONT face="Times New Roman" size=2>Stephen N.
      Rosenfield</FONT></P></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>Title:</FONT></TD>
    <TD noWrap align=left width="49%" colSpan=2>
      <P align=left><FONT face="Times New Roman" size=2>Executive Vice
      President, General Counsel and</FONT></P></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="49%" colSpan=2>
      <P align=left><FONT face="Times New Roman" size=2>Corporate Secretary
      </FONT></P></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><STRONG><FONT face="Times New Roman" size=2>EXHIBIT
INDEX</FONT></STRONG></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=2>Exhibit
No.</FONT></B></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%"><B><FONT face="Times New Roman" size=2>Description</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>99.1</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="96%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Press release dated May 5,
  2016.</FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade size="2">

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>PRESS RELEASE DATED MAY 5, 2016
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<BR>

<P align=right><B><FONT face="Times New Roman" size=2>EXHIBIT 99.1
</FONT></B><B><FONT face="Times New Roman" size=2></FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>P</FONT></B><B><FONT face="Times New Roman" size=1>RESS </FONT></B><B><FONT face="Times New Roman" size=2>R</FONT></B><B><FONT face="Times New Roman" size=1>ELEASE
</FONT></B><B><FONT face="Times New Roman" size=2>D</FONT></B><B><FONT face="Times New Roman" size=1>ATED </FONT></B><B><FONT face="Times New Roman" size=2>M</FONT></B><B><FONT face="Times New Roman" size=1>AY </FONT></B><B><FONT face="Times New Roman" size=2>5, 2016</FONT></B><B><FONT face="Times New Roman" size=2></FONT></B></P><IMG src="geron_8kx6x1.jpg" border=0><BR>
<P align=center><B><FONT face="Times New Roman" size=2>Geron Corporation Reports
First Quarter 2016 Financial Results and Recent Events </FONT></B></P>
<P align=center><I><FONT face="Times New Roman" size=2>Conference Call Scheduled
for 4:30 p.m. EDT Today, May 5 </FONT></I></P>
<P align=left><B><FONT face="Times New Roman" size=2>MENLO PARK,
Calif.,</FONT></B><B><FONT face="Times New Roman" size=2> </FONT></B><B><FONT face="Times New Roman" size=2>May 5, 2016 </FONT></B><FONT face="Times New Roman" size=2>-- Geron Corporation (Nasdaq: GERN) today reported
financial results for the first quarter ended March 31, 2016 and recent events.
</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>First Quarter 2016 Results
</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>For the first quarter of 2016,
the company reported operating revenues of $749,000 and operating expenses of
$9.8 million compared to $537,000 and $10.0 million, respectively, for the
comparable 2015 period. Revenues for the first quarter of 2016 and 2015 included
royalty and license fee revenues under various non-imetelstat agreements.
Operating expenses in the first quarter of 2015 included restructuring charges
of $406,000 in </FONT><FONT face="Times New Roman" size=2>connection with the
company&#146;s organizational resizing announced in March 2015. Net loss for the first
quarter of 2016 was $8.8 million, or $0.06 per share, compared to $9.3 million,
or $0.06 per share, for the comparable 2015 period. The company ended the first
quarter of 2016 with $141.9 million in cash and investments. </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Research and development
expenses for the first quarter of 2016 and 2015 were $5.0 million for each
period. Research and development
expenses for 2016 primarily reflect the net result of </FONT><FONT face="Times New Roman" size=2>higher costs for the company&#146;s proportionate share of clinical development
expenses under the imetelstat collaboration with Janssen Biotech, Inc.
(Janssen), partially offset by lower personnel related expenses as a result of
the 2015 organizational resizing. The company expects research and development
expenses to increase during the remainder of the year as the clinical
development of imetelstat continues in collaboration with Janssen. </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>General and administrative
expenses for the first quarter of 2016 were $4.8 million compared to $4.6
million for the comparable 2015 period. The increase in general and
administrative expenses primarily reflects the net result of higher non-cash
stock-based compensation expense, partially offset by lower personnel related
costs due to the 2015 organizational resizing. </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Interest and other income for
the first quarter of 2016 was $256,000 compared to $149,000 for the comparable
2015 period. The increase in interest and other income in 2016 compared to 2015
primarily reflects higher yields </FONT><FONT face="Times New Roman" size=2>on
the company&#146;s marketable securities portfolio.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Recent Company Events
</FONT></B></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>Clinical Development by
Janssen</FONT></I></B><FONT face="Times New Roman" size=2> </FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>In January 2016, the first patient was dosed
      in a Phase 2/3 clinical trial to evaluate imetelstat in patients with
      myelodysplastic syndromes (MDS). The trial, referred to as
      IMerge<SUP>TM</SUP>, will evaluate imetelstat in transfusion dependent
      patients with International Prognostic Scoring System (IPSS) Low or
      Intermediate-1 risk MDS who have relapsed after or are refractory to prior
      treatment with an erythropoiesis stimulating agent (ESA). </FONT></P>
      <P align=left><FONT face="Times New Roman" size=2>This is the second
      clinical study to be initiated under the terms of the exclusive worldwide
      imetelstat license and collaboration agreement between Geron and Janssen.
      Further information about the trial can be found at https://clinicaltrials.gov/ct2/show/NCT02598661.
      </FONT></P></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>1</FONT><FONT face="Times New Roman" size=2></FONT></P>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><B><I><FONT face="Times New Roman" size=2>Presentations and
Publications</FONT></I></B><FONT face="Times New Roman" size=2> </FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%" colSpan=2>
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>Clinical data on imetelstat safety and
      efficacy from patients with a form of MDS known as refractory anemia with
      ring sideroblasts (MDS-RARS) enrolled as part of the Mayo Clinic Pilot
      Study were published online in the </FONT><I><FONT face="Times New Roman" size=2>Blood Cancer Journal </FONT></I><FONT face="Times New Roman" size=2>in March. The full text paper is available online at
      http://www.nature.com/bcj/. </FONT></P>
      <P align=left><FONT face="Times New Roman" size=2>The data, previously
      presented at the American Society of Hematology annual meeting in December
      2015, included nine patients enrolled in the study cohort, classified as
      having either IPSS intermediate-1 or intermediate-2 risk disease. Six of
      nine (66.7%) patients had prior treatment with ESAs. Three of the eight
      (37.5%) patients who were dependent on red blood cell transfusions at
      study entry became transfusion independent, defined as not requiring
      transfusions for at least eight weeks. The median duration of transfusion
      independence was 28 weeks (range: nine weeks to 37
      weeks).&nbsp;<BR>&nbsp;</FONT><FONT face="Times New Roman" size=2></FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%" colSpan=2>
      <P align=left><FONT face="Times New Roman" size=2>Two poster presentations
      by Janssen and academic collaborators describing non-clinical data on
      imetelstat were made at the 2016 annual meeting of the American
      Association for Cancer Research in April: </FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt" vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%" colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD style="PADDING-RIGHT: 8pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9675;</FONT></TD>
    <TD vAlign=top width="98%">
      <P align=left><U><FONT face="Times New Roman" size=2>Impact of
      hypomethylating agents on hTERT expression and synergistic effect in
      combination with</FONT></U><FONT face="Times New Roman" size=2>
      </FONT><U><FONT face="Times New Roman" size=2>imetelstat, a telomerase
      inhibitor, in AML cell lines (Abstract #2731)</FONT></U><FONT face="Times New Roman" size=2> </FONT></P>
      <P align=left><FONT face="Times New Roman" size=2>Data presented described
      non-clinical results that treating acute myeloid leukemia (AML) cell lines
      with imetelstat enhanced the effects of agents currently used for the
      treatment of AML. These data extend the rationale from prior non-clinical
      studies for the potential use of imetelstat in hematologic myeloid
      malignancies, such as AML, including in combination with standard
      therapies.<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD style="PADDING-RIGHT: 8pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9675;</FONT></TD>
    <TD vAlign=top width="98%">
      <P align=left><FONT face="Times New Roman" size=2><U>Myelosuppression in patients treated with
      the telomerase inhibitor imetelstat is not mediated through activation of toll-like receptors (Abstract #2732)</U></FONT></P>
      <P align=left><FONT face="Times New Roman" size=2>Data presented described
      results from non-clinical studies that provide further evidence for
      potential on-target mechanisms of telomerase inhibition by imetelstat
      underlying the reduction in platelets observed in previously conducted
      imetelstat clinical trials. </FONT></P></TD></TR></TABLE>

<P ALIGN="LEFT" STYLE="margin-left: 15pt"><FONT face="Times New Roman" size=2>The posters are available on
the Presentations &amp; Publications </FONT><FONT face="Times New Roman" size=2>page of Geron&#146;s website at www.geron.com/presentations.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Conference Call
</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>At 4:30 p.m. EDT on May 5,
2016, </FONT><FONT face="Times New Roman" size=2>Geron&#146;s management will host a conference call to discuss the company&#146;s
</FONT><FONT face="Times New Roman" size=2>first quarter results as well as
recent events. </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Participants can access the
conference call live via telephone by dialing 877-303-9139 (U.S.); 760-536-5195
(international). The passcode is 97998290. A live audio-only webcast is also
available at http://edge.media-server.com/m/p/8839g3n8/lan/en. The audio webcast
of the conference call will be available for replay approximately one hour
following the live broadcast through June 5, 2016. </FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>About Geron </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Geron is a biopharmaceutical
company supporting the clinical stage development of a first-in-class telomerase
inhibitor, imetelstat, in hematologic myeloid malignancies. For more information
about Geron, visit www.geron.com. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>2</FONT><FONT face="Times New Roman" size=2></FONT></P>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><B><FONT face="Times New Roman" size=2>Use of Forward-Looking
Statements </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Except for the historical
information contained herein, this press release contains forward-looking
statements made pursuant to the </FONT><FONT face="Times New Roman" size=2>&#147;safe
harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995. Investors are
cautioned that statements in this press release regarding: (i) the conduct and
continuation of IMbark<SUP>TM</SUP> and IMerge<SUP>TM</SUP> and other potential
activities under the collaboration agreement with Janssen; (ii) the safety and
efficacy of imetelstat; (iii) the current timelines, milestones and designs of
IMbark<SUP>TM</SUP> and IMerge<SUP>TM</SUP>, including planned reviews and
analyses of clinical data; (iv) that the data from Abstract #2731 extend the rationale from prior non-clinical studies for the potential use of imetelstat in hematologic myeloid malignancies, such as AML, including in combination with standard therapies; (v) that the data from Abstract #2732 provide further evidence for potential on-target mechanisms of telomerase inhibition by imetelstat underlying the reduction in platelets observed in previously conducted imetelstat clinical trials; (vi) financial projections and expectations; and (vii) other statements that are not historical
facts, constitute forward-looking statements. These statements involve risks and
uncertainties that can cause actual results to differ materially from those in
such forward-looking statements. These risks and uncertainties, include, without
limitation, risks and uncertainties related to: (i) the uncertain,
time-consuming and expensive product development and regulatory process,
including whether Geron and Janssen will succeed in overcoming all of the
clinical safety and efficacy, technical, scientific, manufacturing and
regulatory challenges in the development and commercialization of imetelstat;
(ii) regulatory authorities permitting the current clinical trials to continue
to proceed and potential clinical trials to begin or continue to proceed;
</FONT><FONT face="Times New Roman" size=2>(iii) Janssen&#146;s ability to enroll patients in a timely manner, or at all, in any of the current
or potential clinical trials of imetelstat; (iv) the ability of Geron
</FONT><FONT face="Times New Roman" size=2>and Janssen to protect and maintain
intellectual property rights for imetelstat; (v) Geron&#146;s dependence on Janssen for the development,
regulatory approval, manufacture and commercialization of imetelstat, including
the risks that if Janssen were to breach or terminate the collaboration
agreement or otherwise fail to successfully develop and commercialize imetelstat
and in a timely manner, or at all, Geron would not obtain the anticipated
financial and other benefits of the collaboration agreement with Janssen and the
clinical development or commercialization of imetelstat could be delayed or
terminated; (vi) whether imetelstat is safe and efficacious, and whether any
future efficacy or safety results may cause the benefit/risk profile of
imetelstat to become unacceptable; (vii) whether imetelstat can be applied to
any or to multiple hematologic malignancies; </FONT><FONT face="Times New Roman" size=2>and (viii) Geron&#146;s need for future capital. Additional information on the above risks and uncertainties and additional risks,
uncertainties and factors that could cause actual results to differ materially
from those in the forward-looking
statements are contained in Geron&#146;s periodic reports filed with the Securities and Exchange Commission under the heading &#147;Risk Factors,&#148; including
 Geron&#146;s quarterly report on Form 10-Q for the quarter ended
March 31, 2016. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made, and the facts and
assumptions underlying the forward-looking statements may change. Except as
required by law, Geron disclaims any obligation to update these forward-looking
statements to reflect future information, events or circumstances. </FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>CONTACT: </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Anna Krassowska,
Ph.D.<BR>Investor and Media Relations<BR>650-473-7765<BR> investor@geron.com<BR>media@geron.com
</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Financial table follows.
</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>3</FONT><FONT face="Times New Roman" size=2></FONT></P>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>GERON
CORPORATION<BR></FONT></B><B><FONT face="Times New Roman" size=2>CONDENSED
STATEMENTS OF OPERATIONS<BR></FONT></B><B><FONT face="Times New Roman" size=2></FONT></B><B><FONT face="Times New Roman" size=2>(UNAUDITED)</FONT></B><B><FONT face="Times New Roman" size=2></FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><FONT face="Times New Roman" size=2></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="9%" colSpan=7><B><FONT face="Times New Roman" size=2>Three Months Ended March
      31,</FONT></B><FONT face="Times New Roman" size=2></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><I><FONT face="Times New Roman" size=2>(In thousands, except share and per share data)</FONT></I></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face="Times New Roman" size=2>2016</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face="Times New Roman" size=2>2015</FONT></B> <FONT face="Times New Roman" size=2></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Revenues:</FONT><FONT face="Times New Roman" size=2></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;License fees and
      royalties</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>749</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>537</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Operating expenses:</FONT><FONT face="Times New Roman" size=2></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and
      development</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>5,033</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>4,987</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring
      charges</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>406</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and
      administrative</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>4,793</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>4,600</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
      operating expenses</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>9,826</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>9,993</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><FONT face="Times New Roman" size=2>Loss
      from operations</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(9,077</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>(9,456</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Unrealized gain on derivatives</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>16</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><FONT face="Times New Roman" size=2>Interest and other income</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>256</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>149</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Interest and other expense</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>(21 </FONT><FONT face="Times New Roman" size=2></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT size=2>)</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>(24</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><FONT face="Times New Roman" size=2>Net
      loss</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(8,842</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>) </FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>(9,315 </FONT><FONT face="Times New Roman" size=2></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#cceeff><B><FONT face="Times New Roman" size=2>Basic and diluted net loss per
      share:</FONT></B></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss per
    share</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>(0.06</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>(0.06 </FONT><FONT face="Times New Roman" size=2></FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT size=2>)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares used in computing
      net loss per share</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>158,896,038</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>157,547,568</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff></TD></TR></TABLE><BR>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="99%" colSpan=7><B><FONT face="Times New Roman" size=2>CONDENSED BALANCE SHEETS</FONT></B><B><FONT face="Times New Roman" size=2></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="99%" colSpan=7><B><FONT face="Times New Roman" size=2>&nbsp;</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%"><FONT face="Times New Roman" size=2></FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>March 31,</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>December 31,</FONT></B><FONT face="Times New Roman" size=2></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%"><I><FONT face="Times New Roman" size=2>(In thousands)</FONT></I><FONT face="Times New Roman" size=2></FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="WIDTH: 5%; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" noWrap width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>2016</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="WIDTH: 2%; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" noWrap width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>2015</FONT></B> <FONT face="Times New Roman" size=2></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%"><FONT face="Times New Roman" size=2></FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="4%" colSpan=2><B><FONT face="Times New Roman" size=2>(Unaudited)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=2>(Note 1)</FONT></B><B><FONT face="Times New Roman" size=2></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Current assets:</FONT><FONT face="Times New Roman" size=2></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><B><FONT face="Times New Roman" size=2></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash, cash equivalents
      and restricted cash</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>13,069</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>21,515</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current marketable
      securities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>96,846</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>92,524</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current
      assets</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>1,040</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>1,853</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
      current assets</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>110,955</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>115,892</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#cceeff><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%"><FONT face="Times New Roman" size=2>Noncurrent marketable securities</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>31,976</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>32,661</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Property and equipment, net</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>212</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>207</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%"><FONT face="Times New Roman" size=2></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>143,143</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>148,760</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#cceeff><FONT face="Times New Roman" size=2>Current liabilities</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>6,658</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>6,634</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%"><FONT face="Times New Roman" size=2>Stockholders&#146; equity</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>136,485</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>142,126</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="91%" bgColor=#cceeff></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#cceeff><FONT face="Times New Roman" size=2>143,143</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#cceeff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#cceeff><FONT face="Times New Roman" size=2>148,760</FONT></TD></TR></TABLE></DIV><BR>
<TABLE style="LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=left width="1%"><FONT size=2 face="Times New Roman"><STRONG>Note 1</STRONG><FONT face="Times New Roman" >:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT></TD>
    <TD align=left width="99%"><FONT face="Times New Roman" size=2 >Derived from audited financial
      statements included in the company&#146;s annual report on Form 10-K for the
      year ended December 31, 2015.</FONT><FONT face="Times New Roman" size=2 ></FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>###</FONT><FONT face="Times New Roman" size=2></FONT></P>
<HR align=center width="100%" noShade size="2">

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>geron_8kx6x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron_8kx6x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  S &$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Z)_X*-_M]
M?\%;_P!O3_@K9\0O^"3/_!*#XBV'[/WA3]GO0],O_C+\8XC::+?-?1:-X>U+
MQEXI\7>/WT7Q1K_AKP;X:U;QIH'@30/#/@71HO$FO>*8+R[O)]4L;ZUM]!\D
M_9V_X*%?\%D_^"1/_!4;]GW]@?\ X*H?%>V_:A_9[_:B\6^$O!'@3XPW\*:M
M9BX^(6MZ;X6TKQW\/?B?=>%?#'C+4!X.\:ZSI.B?$GP+X]MKZ32=(G>^TBSL
M+>_\/:UJ_P!*?\$C?^5H+_@M[_V(^K_^K'^#7\A7'_\ !TL3_P /$/\ @@=Z
M']I;4_\ U>'[+/;Z'O\ XX /[$?CI\9/!'[.WP6^+'QZ^)5[-IWP^^#/P[\8
M_$[QG>VT0N+J'PUX(T&_\1:N;.W+(+B]>RT^6*SM]Z>?=/%#O7?N'\#7[.7Q
M4_X.5?\ @NE??&W]JW]EC]J:U_9!_9I\->-/$^E_!?PE>ZR?AEX8UR2PNYKK
M3_AYX8U+PA\.O$6O_$/4/#EA)IVF^,/'GCJ\;0&\03S6=K<1>3?:/HO]@O\
MP6A_Y1*_\%'?^S-OC]_ZKO7*_/+_ (-/#_QI-_9W'/'Q$_:'Q[#_ (77XR./
M;DDX]R?6@#P3_@W=_P""O?[4W[3WQ2_:1_X)P_\ !1E$/[:7[+$FLWEOXEET
M+1O#^M^+O"_@KQ'8^ _B!H?C6V\-BW\.7WB_P/XKO]&DM_$F@:?8V'BWP]X@
M@O)(KF\TNYUG6_TZ_P""UO\ P5A\(?\ !(W]DEOC5/X8L?B)\7OB#XB?X=?
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M\H?;S_LYWX(_^DOC>OVH_P""67_*-'_@G]_V9I^S9_ZJ'PC0!_(3\1_V]_\
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M/A*]&F:GXAT:U=-,U^]>X:[$EHMQ##<21?R9?\'NO_(@_P#!.?\ [*3\=?\
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M#_@L]_V<O\+O_4A_:7KYJ_X+V?\ *T5_P1@_[&;_ ()[?^MY>,Z /[^J***
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=@#[-HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
